Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

Journal of Clinical Oncology

Volumn 13, Issue 9, 1995, Pages 2281-2292

  Valone, Frank H ^a   Kaufman, Peter A ^b   Guyre, Paul M ^b   Lewis, Lionel D ^b   Memoli, Vincent ^b   Deo, Yashwant ^b   Graziano, Robert ^b   Fisher, Jan L ^b   Meyer, Louise ^b   Mrozek Orlowski, Mary ^b   Wardwell, Kathleen ^b   Guyre, Veronica ^b   Morley, Theresa L ^b   Arvizu, Christine ^b   Fanger, Michael W ^b  

^a Activated Cell Therapy   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CYTOKINE; DIPHENHYDRAMINE; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LORAZEPAM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 210; NEOPTERIN; ONCOPROTEIN; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; EFFECTOR CELL; FEMALE; FEVER; GENE EXPRESSION; HUMAN; HYPOTENSION; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MALAISE; MAXIMUM PERMISSIBLE DOSE; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTO ONCOGENE; TISSUE DISTRIBUTION;

EID: 0029095589     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.9.2281     Document Type: Article

References (40)

1. Schlom J: Basic principles and applications of monoclonal antibodies in the management of carcinomas. Cancer Res 46:3225-3238, 1986
2. Dillman, RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515, 1994
3. Fanger MW, Morganelli PM, Guyre PM: Use of bispecific antibodies in the therapy of tumors. Cancer Treat Res 68:181-194, 1993
4. Fanger MW, Segal DM, Romet-Lemonne JL: Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 12:51-54, 1991
5. Perez P, Hoffman RW, Shaw S, et al: Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354-356, 1985
6. van Dijk J, Warnaar SO, van Eendenburg JDH, et al: Induction of tumor-cell lysis by bs-mAb recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43:344-349, 1989
7. Weiner GJ, Kostelny SA, Hillstrom JR, et al: The role of T cell activation in anti-CD3 X antitumor bispecific antibody therapy. J Immunol 152:2385-2392, 1994
8. Weiner LM, Holmes M, Adams GP, et al: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94-100, 1993
9. Weiner LM, Holmes M, Richeson A, et al: Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 151:2877-2886, 1993
10. Valerius T, Repp R, de Wit TP, et al: Involvement of the high-affinity receptor for TgG (Fc gamma RI: CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931-939, 1993
11. Guyre PM, Graziano RF, Vance BA, et al: Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650-1655, 1989
12. Shen L, Guyre PM, Anderson CL, et al: Heteroantibody-mediated cytotoxicity: Antibody to the high-affinity Fc receptor for IgG mediates cytotoxicity by human monocytes which is enhanced by interferon-gamma and is not blocked by human IgG. J Immunol 137:3378-3382, 1986
13. Ring DB, Clark R, Saxena A: Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol Immunol 28:915-917, 1991
14. Van de Winkel JGJ, Capel PJA: Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol Today 14:215-221, 1993
15. Maguire HCJ, Greene MI: The neu (c-erbB-2) oncogene. Semin Oncol 16:148-155, 1989
16. Samon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
17. Levine MN, Andrulis I: The HER-2/neu oncogene in breast cancer: So what is new? J Clin Oncol 10:1034-1035, 1992
18. Ornstein DL, Zacharski LR, Memoli V, et al: Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of lung tissues. Cancer:1061-1067, 1991
19. Corbett IP, Henry JA, Angus B, et al: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161:15-25, 1990
20. 2 antibody containing thioetherlinked Fab′γ fragments. J Immunol 139:2367-2375, 1987
21. Guyre PM, Campbell AS, Kniffin WD, et al: Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors. J Clin Invest 86:1892-1896, 1990
22. Backman KA, Guyre PM: Gamma-interferon inhibits Fc receptor II-mediated phagocytosis of tumor cells by human macrophages. Cancer Res 54:2456-2461, 1994
23. Looney RJ, Abraham GN, Anderson CL: Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641-1647, 1986
24. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-997, 1987
25. Feinberg B, Kurzrock R, Talpaz M, et al: A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 8:1328-1334, 1988
26. Weber J, Yang JC, Topalian SL, et al: Phase I trial of subcutaneous Interleukin-6 in patients with advanced malignancies. J Clin Oncol 11:499-506, 1993
27. Kipps TJ, Parham P, Punt J, et al: Importance of immunoglobulin isotype in human antibody-dependent, cell mediated cytotoxicity directed by mouse monoclonal antibodies. J Exp Med 161:1-17, 1985
28. Perez-Soler R, Donato NJ, Shin DM, et al: Tumor epidermal growth factor receptor studies in patients with non-small cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12:730-739, 1994
29. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183, 1994
30. Weiner LM, Ring D, Li W, et al: Phase I trial of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and CD16. Proc Am Soc Clin Oncol 13:33A, 1994 (abstr)
31. Tibben JG, Boerman OC, Claessens RA, et al: Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab′)2. J Natl Cancer Inst 85:1003-1004, 1993 (letter)
32. Kroesen BJ, ter Haar A, Spakman H, et al: Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 37:400-407, 1993
33. Chatenoud L, Legendre C, Kurrle R, et al: Absence of clinical symptoms following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. Transplantation 55:443-445, 1993
34. Polat GL, Laufer J, Fabian I, et al: Cross-linking of monocyte plasma membrane Fc alpha. Fc gamma or mannose receptors induces TNF production. Immunology 80:287-292, 1993
35. Krutmann J, Kirnbauer R, Kock A, et al: Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol 145:1337-1342, 1990
36. Ishiguro A, Nakahata T, Koike K, et al: Induction of granulocyte and granulocyte-macrophage colony-stimulating factors from human monocytes stimulated by Fc fragments of human IgG. Br J Haematol 79:14-21, 1991
37. Kopp WC, Smith JW, Ewel CH, et al: Immunomodulatory effects of interferon-γ in patients with metastatic malignant melanoma. J Immunother 13:181-190, 1993
38. Goodman GE, Hellstrom I, Brodzinsky L, et al: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol 8:1083-1092, 1990
39. Gallinger S, Reilly RM, Kirsh JC, et al: Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 53:271-278, 1993
40. 2 and Fab′ in mice. Cancer Res 46:3969-3978, 1986